Vertex, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERX research report →
Range $15 – $18
Price Chart
About the company
Vertex, Inc. specializes in delivering advanced tax technology solutions to corporations across various sectors, including retail, communication, leasing, and manufacturing. These services are provided to clients both within the United States and globally.
- CEO
- Christopher David Young
- IPO
- 2020
- Employees
- 2,000
- HQ
- King of Prussia, PA, US
Get TickerSpark's AI analysis on VERX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $2.80B
- P/E
- -61.13
- Fwd P/E
- 20.36
- PEG
- -0.02
- P/S
- 3.49
- P/B
- 15.64
- EV/EBITDA
- 54.46
- Div Yield
- 0.00%
- Gross Margin
- 62.76%
- Op Margin
- -0.67%
- Net Margin
- -5.83%
- ROE
- -20.33%
- ROIC
- 1.29%
Latest fiscal year · YoY change
- Revenue
- $748.44M+12.2%
- Gross Profit
- $454.51M+6.7%
- Op Income
- $-7,846,000
- Net Income
- $7.21M+113.7%
- EPS
- $0.05+114.7%
- OCF Growth
- +0.4%
- FCF Growth
- -38.8%
- 52W High
- $20.82
- 52W Low
- $10.21
- 50D MA
- $14.18
- 200D MA
- $13.18
- Beta
- 0.75
- RSI (14)
- 62
- Avg Volume
- 1.44M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vertex posted a strong Q3 with revenue above guidance, sharply higher profitability and cash flow, while e-invoicing and cloud momentum improved and full-year guidance was raised.· November 4, 2026
- Q3 revenue was $213.3 million, up 11% year over year and above the high end of guidance.
- Adjusted EBITDA was $64.8 million, up nearly 50% year over year, with margin at 30.4% versus 27% plus a year ago.
- ARR rose 11.7% to $724.3 million, cloud revenue growth accelerated to more than 20%, and e-invoicing ARR was up over 100% year over year.
- Gross margin improved materially: non-GAAP gross margin was 77.6%, with software subscription gross margin at 84.6% and services gross margin at 37.7%.
- Management raised full-year guidance and said the Q4 outlook includes a roughly $1 million headwind from losing an OEM in payroll tax.
Vertex reported third-quarter revenue of $213.3 million, up 11% year over year and above the high end of guidance. Software subscription revenue increased 10.2% and services revenue increased 15.8%. Annual recurring revenue rose 11.7% to $724.3 million, gross revenue retention was 95%, and net revenue retention improved to 106%. Non-GAAP gross margin was 77.6%, up 370 basis points year over year; software subscription gross margin was 84.6%, up 316 basis points; and services gross margin was 37.7%, up 886 basis points. Adjusted EBITDA was $64.8 million, up approximately 50% year over year and about $8 million above the high end of guidance, with adjusted EBITDA margin at 30.4%. Free cash flow was $25.2 million, pro forma free cash flow was $33.8 million, and cash EBITDA was $36.7 million versus $11.2 million a year ago. For Q4, Vertex guided to revenue of $215 million to $217 million and adjusted EBITDA of $58 million to $60 million. For the full year, revenue guidance was raised to $828.9 million to $830.9 million and adjusted EBITDA guidance was raised to $217.9 million to $219.9 million; cloud revenue growth is now expected to be 19% for the full year. Management said GRR and NRR should each decline by about 1 point in Q4 due to the loss of an OEM in payroll tax, with the financial impact already included in guidance.
Chris Young emphasized that Vertex is delivering on the priorities set earlier in the year: stabilizing the core business, improving operating discipline, and building a stronger foundation for growth. He pointed to improved customer retention, stronger ARR and cloud growth, and the rapid expansion of e-invoicing as evidence that the business is re-accelerating in the core. His tone was upbeat and confident, especially around Vertex Sol, AI-driven productivity, and the company’s ability to become a more connected tax and compliance platform.
John Schwab focused on the improved financial profile and the conversion of earnings into cash. He highlighted that non-GAAP gross margin reached 77.6%, adjusted EBITDA rose to $64.8 million, and cash EBITDA increased to $36.7 million from $11.2 million a year ago, reflecting both higher earnings and more capital efficiency. He also said the Value Creation Plan is flowing through the business, that Q4 guidance includes marketing tied to Vertex Exchange and targeted growth investments, and that the buyback program has repurchased $83.6 million of the $150 million authorization, leaving $66.4 million remaining.
Analysts focused on Vertex Exchange feedback, Sol pricing, the French e-invoicing rollout, cloud migrations, and the payroll OEM loss. Management said the event feedback was “extremely positive,” and explained that Sol will have a mixed pricing model: some capabilities are included in the platform while others will carry separate charges. On France, management said the rollout went very well, helped drive the 100% ARR growth in e-invoicing, and could create follow-on consolidation opportunities. On the payroll OEM issue, management called it a discrete and meaningful loss worth disclosing, said it will reduce GRR and NRR by about 1 point in Q4, and stressed it does not indicate broader customer deterioration.
The call showed clear momentum in the core business: revenue beat, EBITDA margin expanded, ARR improved, and cloud growth accelerated. Management also sounded increasingly constructive on e-invoicing, citing strong French execution, over-100% ARR growth, new partner momentum like Avanade, and upcoming mandates across Europe that could extend the runway.
Management flagged a discrete payroll OEM loss that will pressure Q4 retention metrics and slightly temper revenue relative to prior expectations. They also cautioned that e-invoicing growth at this pace will not be linear every quarter, and that some of the current margin upside is still being balanced against reinvestment in growth, Exchange marketing, and future product development.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.1%
- Shares Outstanding
- 162.27M
- Float Shares
- 144.54M
of shares held by institutions
235 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.35M | ▼ 38.53K |
| Blackrock, Inc. | 6.49M | ▲ 249.91K |
| Vanguard Portfolio Management LLC | 5.17M | ▲ 182.83K |
| Brown Advisory Inc | 3.55M | ▲ 1.74M |
| Vanguard Capital Management LLC | 3.17M | ▼ 3.15K |
| Tensile Capital Management LP | 2.90M | ▼ 500.00K |
| D. E. Shaw & Co., Inc. | 2.19M | ▲ 550.90K |
| State Street Corp | 2.03M | ▼ 33.67K |
| Arrowstreet Capital, Limited Partnership | 1.81M | ▲ 338.85K |
| Jpmorgan Chase & Co | 1.80M | ▼ 725.26K |
| Nomura Holdings Inc | 1.66M | ▼ 957.54K |
| Geode Capital Management, LLC | 1.56M | ▼ 274.92K |
Held by 217 ETFs
Biggest fund positions in VERX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Young Christopher David | other | 325,182 |
| Nov 10, 26 | Young Christopher David | other | 325,182 |
| Nov 10, 26 | Young Christopher David | other | 157,058 |
| Nov 9, 26 | Leib Ryan J | sell | 6,963 |
| Oct 7, 26 | Saha Debanjan | other | 11,199 |
| Oct 7, 26 | Saha Debanjan | other | 0 |
| Jun 10, 26 | DeStefano David | other | 15,638 |
| Jun 10, 26 | Gayton Bradley M | other | 15,638 |
| Jun 10, 26 | Saunders Philip Seth | other | 15,638 |
| Jun 10, 26 | Radcliffe Amanda Westphal | other | 15,638 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VERX coverage
Recent articles, reports, and earnings notes.
No research on VERX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VERX report →Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst
seekingalpha.com · Nov 20
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 17
Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
marketbeat.com · Nov 17
Vertex Survey: Inaccurate Checkout Totals Are the Top Trust Breaker for 2026 Holiday Shoppers
globenewswire.com · Nov 17
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
marketbeat.com · Nov 16
Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It
seekingalpha.com · Nov 13
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 11
Only One in Six Enterprises Treats Indirect Tax as a Standing Board Item
globenewswire.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.